Home > Insider Trading > Filing (0001209191-24-002643)

Filing Details

Accession Number:: 0001209191-24-002643
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-02-02 16:32:53
Reporting Period:: 2024-01-31

Accepted Time:: 2024-02-02 16:32:53
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1516551	Skye Bioscience Inc.	SKYE	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1219014	M Scott Rocklage	C/O 5Am Venture Management, Llc 501 2Nd Street, Suite 350 San Francisco CA 94107	No	No	Yes	No
1240357	D John Diekman	C/O 5Am Venture Management, Llc 501 2Nd Street, Suite 350 San Francisco CA 94107	No	No	Yes	No
1386509	5Am Ventures Ii Lp	501 2Nd Street, Suite 350 San Francisco CA 94107	No	No	Yes	No
1390376	5Am Co-Investors Ii Lp	501 2Nd Street, Suite 350 San Francisco CA 94107	No	No	Yes	No
1555952	5Am Partners Ii, Llc	501 2Nd Street, Suite 350 San Francisco CA 94107	No	No	Yes	No
1664281	Kush Parmar	C/O 5Am Venture Management, Llc 501 2Nd Street, Suite 350 San Francisco CA 94107	No	No	Yes	No
1844435	5Am Ventures Vii, L.p.	501 2Nd Street, Suite 350 San Francisco CA 94107	No	No	Yes	No
1873545	5Am Partners Vii, Llc	501 2Nd Street, Suite 350 San Francisco CA 94107	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-01-31	5,206,074	$2.31	7,943,520	No	4	P	Indirect	By 5AM Ventures VII, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By 5AM Ventures VII, L.P.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,718,189	Indirect	By 5AM Ventures II, L.P.
Common Stock	67,796	Indirect	By 5AM Co-Investors II, L.P.

Footnotes

The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.